Product Information
VENLAFAXINE HCL ER 150 MG CAP is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.1333 per EA under NDC 33342019607. Its NADAC has been published 289 times since Feb 12, 2020.
FDA first approved this application on Oct 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342019607
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/20/2025
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204889FDA Approved
10/5/2017
TE Code
AB
On Market Since
10/6/2017
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 150 MG CAP has been published 289 times since Feb 12, 2020, and over the history we have for it it has declined 26.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1333 per EA |
|---|---|
| All-time high | $0.2086 (Aug 11, 2021) |
| All-time low | $0.1057 (Nov 20, 2024) |
| Median price | $0.1558 |
| Average price | $0.1587 |
| Largest weekly change | +21.6% (Aug 21, 2024) |
| Weeks tracked | 289 |
| Tracking since | Feb 12, 2020 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-11.2%
5Y
-23.2%
All
-26.8%
Last surveyed Aug 20, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Venlafaxine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Venlafaxine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 150 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 150 MG CAP, manufactured by Macleods Pharmaceuticals Limited, is $0.1333 per EA (NDC 33342019607), effective Aug 20, 2025.
How has the price of VENLAFAXINE HCL ER 150 MG CAP changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has declined 26.8%. It has been tracked across 289 weekly CMS publications since Feb 12, 2020.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 150 MG CAP?
Since Feb 12, 2020, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has ranged from a low of $0.1057 (Nov 20, 2024) to a high of $0.2086 (Aug 11, 2021), with a median of $0.1558 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 150 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of VENLAFAXINE HCL ER 150 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VENLAFAXINE HCL ER 150 MG CAP?
VENLAFAXINE HCL ER 150 MG CAP (NDC 33342019607) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.